News archive search

Search the Newsreel

Search stored headlines and summaries, then narrow the results by company, country, sector, industry, source or date.

Showing
1–16
Matches
16
Sources here
5
Companies here
1
Search results Stored financial headlines

Active search

16 matching headlines

Ticker or company: CMMBMain company stories
Clear
Latest

Stock Titan Deals and strategy

Chemomab Therapeutics (CMMB) gains 5.2% stake holder in Touchstone Global

Touchstone Global Investments Pty Ltd has reported a 5.2% passive stake in Chemomab Therapeutics Ltd. (CMMB), holding 377,814 American Depositary Shares (ADSs). This disclosure, filed on a Schedule 13G, indicates that Touchstone Global has sole voting and dispositive power over these shares, with each ADS representing 80 ordinary shares. The filing signals a significant, yet passive, ownership interest …

Main company 🇺🇸 United States
Read at Stock Titan
Sharemaestro market context Trend signal started 52 weeks -46.3% · Next-week setup negative 39.4% CMMB stored weekly price path from 22 Aug 2025 to 14 Aug 2026
Just inNext headlines
Stock Titan Market update Main company 🇺🇸 United States

Chemomab Therapeutics (CMMB) holder Erik Otto reports 1.2% ADS ownership

Erik Otto, an investor in Chemomab Therapeutics Ltd. (CMMB), has filed an amended Schedule 13G, disclosing beneficial ownership of 90,000 American Depository Shares (ADSs), which represents 1.2% of the company's outstanding ADSs. Each ADS represents twenty ordinary shares. Otto holds sole voting and dispositive …

CMMB main company
Sharemaestro market context Trend signal started 52 weeks -46.3% · Next-week setup negative 39.4% CMMB stored weekly price path from 22 Aug 2025 to 14 Aug 2026
TradingKey Earnings Main company 🇺🇸 United States

Chemomab Therapeutics Ltd (CMMB) Earnings Forecast: Future EPS & Revenue Growth Estimates

Chemomab Therapeutics Ltd (CMMB) has a "Strong Buy" rating based on 2 analysts, with a target price of USD 26.50, representing a potential upside of 733.33%. The company's previous quarter's EPS was USD -0.24, slightly below the market expectation of USD -0.22, with the …

CMMB main company
Sharemaestro market context Trend signal started 52 weeks -46.3% · Next-week setup negative 39.4% CMMB stored weekly price path from 22 Aug 2025 to 14 Aug 2026

Search results

Matching headlines

External headlines link to their original source. Market context comes from stored weekly company data, not from an opinion about the article.

Simply Wall Street Deals and strategy Main company 🇺🇸 United States

Chemomab Therapeutics (Nasdaq:CMMB) - Stock Analysis

Chemomab Therapeutics (Nasdaq:CMMB) is a clinical-stage biotechnology company focused on treatments for fibrotic and inflammatory diseases. The company faces significant risks, including a highly volatile share price, shareholder dilution, and projected earnings decline, with recent news dominated by a proposed reverse merger with Scipher …

CMMB main company
Sharemaestro market context Trend signal started 52 weeks -46.3% · Next-week setup negative 39.4% CMMB stored weekly price path from 22 Aug 2025 to 14 Aug 2026
TradingKey Earnings Main company 🇺🇸 United States

CMMB Financials

This article provides a detailed financial overview of Chemomab Therapeutics Ltd (CMMB), including its latest stock price, market capitalization, and P/E ratio. It presents a comprehensive look at the company's income statement, balance sheet, and cash flow statement, offering quarterly and annual data for …

CMMB main company
Sharemaestro market context Trend signal started 52 weeks -46.3% · Next-week setup negative 39.4% CMMB stored weekly price path from 22 Aug 2025 to 14 Aug 2026
TradingKey Market update Main company 🇺🇸 United States

Chemomab Therapeutics Ltd (CMMB) Technical Analysis: Support, Resistance, Indicators & Moving Averages

This article provides a technical analysis of Chemomab Therapeutics Ltd (CMMB) stock, focusing on various indicators and moving averages. It presents a summary of buy, sell, and neutral signals from indicators such as MACD, RSI, and TRIX, alongside moving averages like MA5 and MA10. …

CMMB main company
Sharemaestro market context Trend signal started 52 weeks -46.3% · Next-week setup negative 39.4% CMMB stored weekly price path from 22 Aug 2025 to 14 Aug 2026
TradingKey Market update Main company 🇺🇸 United States

Chemomab Therapeutics Ltd (CMMB) Institutional Confidence

This article provides details on the institutional confidence in Chemomab Therapeutics Ltd (CMMB), including its stock performance and key shareholder activities. It lists several institutional and individual shareholders, along with the shares they hold and their percentage change. The stock closed at $1.410 with …

CMMB main company
Sharemaestro market context Trend signal started 52 weeks -46.3% · Next-week setup negative 39.4% CMMB stored weekly price path from 22 Aug 2025 to 14 Aug 2026
TradingKey Earnings Main company 🇺🇸 United States

Chemomab Therapeutics Ltd

This article provides an overview of Chemomab Therapeutics Ltd (CMMB) stock performance, showing a closing price of $1.360 with a -2.86% change. It highlights that critical revenue breakdown data by business segments and regions have not yet been disclosed by the company. The page …

CMMB main company
Sharemaestro market context Trend signal started 52 weeks -46.3% · Next-week setup negative 39.4% CMMB stored weekly price path from 22 Aug 2025 to 14 Aug 2026
TradingKey Deals and strategy Main company 🇺🇸 United States

Chemomab Therapeutics Ltd (CMMB) Dividends & Stock Splits: Historical Payouts and Event Timeline

This article provides historical dividend and stock split information for Chemomab Therapeutics Ltd (CMMB). It notes that no dividends have been distributed over the past five years, but lists several stock splits, including a 4:1 merger in August 2025 and multiple 16:1 mergers in …

CMMB main company
Sharemaestro market context Trend signal started 52 weeks -46.3% · Next-week setup negative 39.4% CMMB stored weekly price path from 22 Aug 2025 to 14 Aug 2026
TradingKey Earnings Main company 🇺🇸 United States

Chemomab Therapeutics Ltd (CMMB) Valuation: PE, PB & Fair Value Analysis

This article provides a brief valuation analysis for Chemomab Therapeutics Ltd (CMMB), noting key financial metrics. As of the close on July 24th, CMMB had a market cap of $39.17 million and a P/E TTM of 7.81. However, specific P/E, P/B, and P/CF data …

CMMB main company
Sharemaestro market context Trend signal started 52 weeks -46.3% · Next-week setup negative 39.4% CMMB stored weekly price path from 22 Aug 2025 to 14 Aug 2026
TradingKey Market update Main company 🇺🇸 United States

Chemomab Therapeutics Ltd (CMMB) Risk Assessment: Volatility, Financial Risk & Investment Risk

This article provides a risk assessment for Chemomab Therapeutics Ltd (CMMB), focusing on volatility, financial risk, and investment risk. It presents various financial metrics such as Beta, VaR, Maximum Drawdown, Volatility, Return Best/Worst Daily Return, Sharpe Ratio, Skewness, Realised Volatility, Standardised True Range, Downside …

CMMB main company
Sharemaestro market context Trend signal started 52 weeks -46.3% · Next-week setup negative 39.4% CMMB stored weekly price path from 22 Aug 2025 to 14 Aug 2026
TradingView Earnings Main company 🇺🇸 United States

Chemomab Therapeutics Ltd. Revenue Breakdown – NASDAQ:CMMB

This article provides financial information for Chemomab Therapeutics Ltd. (NASDAQ: CMMB) on TradingView. It indicates that the market is closed with no recent trades. The content focuses on an overview of financial data, segments, and other fundamental statistics for the company.

CMMB main company
Sharemaestro market context Trend signal started 52 weeks -46.3% · Next-week setup negative 39.4% CMMB stored weekly price path from 22 Aug 2025 to 14 Aug 2026
TradingKey Earnings Main company 🇺🇸 United States

CMMB|Chemomab Therapeutics Ltd|Price:1.800|Chg%:+0.050

This article provides a stock score and comprehensive analysis of Chemomab Therapeutics Ltd (CMMB) from TradingKey. It details how TradingKey generates its stock scores across six dimensions: financial health, company profile, earnings forecasts, price momentum, institutional confidence, and risk assessment. The article states that …

CMMB main company
Sharemaestro market context Trend signal started 52 weeks -46.3% · Next-week setup negative 39.4% CMMB stored weekly price path from 22 Aug 2025 to 14 Aug 2026
Quartr Deals and strategy Main company 🇺🇸 United States

Chemomab Therapeutics (CMMB) Q4 2025 earnings summary

Chemomab Therapeutics reported its Q4 2025 earnings, highlighting a positive FDA End-of-Phase 2 meeting for nebokitug in PSC, paving the way for a single Phase 3 trial. The company also announced strong financial management with a cash runway expected through Q1 2027 and reduced …

CMMB main company
Sharemaestro market context Trend signal started 52 weeks -46.3% · Next-week setup negative 39.4% CMMB stored weekly price path from 22 Aug 2025 to 14 Aug 2026
Quartr Earnings Main company 🇺🇸 United States

Chemomab Therapeutics (CMMB) H.C. Wainwright 27th Annual Global Investment Conference summary

Chemomab Therapeutics (CMMB) presented positive Phase II results for nebokitug, a potential first-in-class treatment for primary sclerosing cholangitis (PSC), at the H.C. Wainwright 27th Annual Global Investment Conference. The drug met safety and efficacy endpoints, leading to FDA alignment for a single pivotal Phase …

CMMB main company
Sharemaestro market context Trend signal started 52 weeks -46.3% · Next-week setup negative 39.4% CMMB stored weekly price path from 22 Aug 2025 to 14 Aug 2026
Stock Titan Deals and strategy Main company 🇺🇸 United States

HBM boosts Chemomab Therapeutics Ltd. (CMMB) stake amid Scipher merger plan

HBM Healthcare Investments (Cayman) Ltd. has significantly increased its beneficial ownership in Chemomab Therapeutics Ltd. (CMMB) to approximately 12.5%, amidst Chemomab's planned merger with Scipher Medicine Corporation. HBM will vote its shares in favor of the merger, which includes contingent value rights for current …

CMMB main company
Sharemaestro market context Trend signal started 52 weeks -46.3% · Next-week setup negative 39.4% CMMB stored weekly price path from 22 Aug 2025 to 14 Aug 2026

Find financial news

Search the Newsreel

Use one field or combine several. Results are newest first.

Evidence context